CRTC1 knockdown potentiated the therapeutic efficacy of atezolizumab, evidenced by xenograft tumor regression, increased CXCL10/11 expression, and elevated serum concentrations of IFN-γ and IL-2. This evidence concerns the gene CXCL10 and neoplasm.